Menu
Recruiting NCT07479641

A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants

Phase I Interventional Cardiomyopathy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Test formulation of HRS-1893 tablet, Reference formulation of HRS-1893 tablet.
Who it may be relevant to
Registry conditions: Cardiomyopathy. Basic parameters: 18 years — 55 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.

Interventions

  • Drug Test formulation of HRS-1893 tablet
    Test formulation of HRS-1893 tablet, oral.
  • Drug Reference formulation of HRS-1893 tablet
    Reference formulation of HRS-1893 tablet, oral.

Primary outcome measures

  • Peak concentration (Cmax). [Time frame: From Day 1 to Day 17.]
  • Area under the plasma concentration - time curve from Time 0 to the last quantifiable time point (AUC0-t). [Time frame: From Day 1 to Day 17.]
  • Area under the plasma concentration - time curve from Time 0 to infinity (AUC0-∞). [Time frame: From Day 1 to Day 17.]
Secondary outcome measures (8)
  • Time to peak concentration (Tmax). [Time frame: From Day 1 to Day 17.]
  • Elimination half-life (t1/2). [Time frame: From Day 1 to Day 17.]
  • Apparent clearance (CL/F). [Time frame: From Day 1 to Day 17.]
  • Apparent volume of distribution (Vz/F). [Time frame: From Day 1 to Day 17.]
  • Incidence and severity of any adverse events (AEs). [Time frame: From Day 1 to Day 21 ± 2.]
  • 12-Lead Electrocardiogram (ECG) QT Interval. [Time frame: From Day 1 to Day 21 ± 2.]
  • Transthoracic echocardiogram (TTE) results. [Time frame: From Day 1 to Day 21 ± 2.]
  • Vital signs results - blood pressure. [Time frame: From Day 1 to Day 21 ± 2.]

Eligibility criteria

Inclusion criteria

  • Subjects aged 18 to 55 years (inclusive), regardless of gender;
  • Body mass index (BMI) between 19 and 28 kg/m² (inclusive), with body weight ≥ 50.0 kg and < 90.0 kg for men, and ≥ 45.0 kg and < 90.0 kg for women;
  • No abnormalities of clinical significance are found upon comprehensive physical examination and laboratory tests, or only minor abnormalities that are deemed by the investigator not to affect the subject's eligibility for enrollment;
  • No clinically significant abnormalities on the 12-lead ECG;
  • The subject must understand the study procedures and methods, voluntarily agree to participate, and provide written informed consent.

Exclusion criteria

  • Subjects with suspected hypersensitivity to the investigational drug or any excipient;
  • The subject has a history of syncope;
  • Exclusion due to blood pressure: Systolic Blood Pressure (SBP) >140 mmHg or <90 mmHg; OR Diastolic Blood Pressure (DBP) >90 mmHg or <60 mmHg, as determined by the investigator to be clinically significant;
  • History of gastric or intestinal surgery that, in the investigator's judgment, may affect drug absorption;
  • A positive result in any one of the following infectious disease screening tests during the screening period: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), treponema pallidum antibody (syphilis), or human immunodeficiency virus antibody/antigen (HIV-Ab/Ag);
  • Subjects who meet any of the following criteria will be excluded: a. Smoking: Average daily cigarette consumption of more than 5 cigarettes within the 4 weeks prior to screening; b. Alcohol: Average daily alcohol intake exceeding 15 g within one week prior to screening (15 g of alcohol is equivalent to 450 mL of beer, 150 mL of wine, or 50 mL of low-alcohol spirits); c. Non-compliance: Inability or unwillingness to abstain from smoking, alcohol, and caffeine-containing foods or beverages during the screening period and the entire study duration; d. Diet: Have special dietary requirements, cannot comply with the standardized diet provided in the study, or have a history of substance abuse;
  • History of substance abuse;
  • Use of any prescription drugs, over-the-counter medications, or Chinese herbal medicines within 1 month prior to dosing, or the use of any drug within 5 half-lives prior to screening (whichever is longer). Additionally, subjects who plan to take any non-study medications during the trial period will be excluded;
  • Any other circumstances that, in the investigator's judgment, make the subject unsuitable for participation in the trial. This includes physiological or psychological conditions that may increase the trial risk, affect the subject's protocol compliance, or impact the subject's ability to complete the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Beijing Hospital — Beijing

Identifiers

NCT: NCT07479641 · HRS-1893-108

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗